S-1 · resale registration
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
IMDX$2.87+0.35%
Insight Molecular Diagnostics Inc.
Sector: In Vitro & In Vivo Diagnostic SubstancesIndustry: Medical - Diagnostics & ResearchCountry: USExchange: Nasdaq
Mkt Cap:$93.92M
Float & O/S:
Inst Own:
DilutionScan read 37 of Insight Molecular Diagnostics Inc.'s SEC filings and found 10 warrant series, 1 convertible, 2 ATM programs, 3 shelf registrations, 1 S-1 registration and 1 completed offering on file for IMDX. The latest dilution event on file is an offering on Feb 12, 2026. Analysis updated Nov 1, 2026.
Signal8 Summary
IMDX
Cash-strapped, heavily diluting micro-cap
Snapshot
iMDx is a tiny diagnostics company still pre-commercial scale, with FY 2025 revenue of just $4.1M despite doubling YoY, and a net loss of $50.2M.
What's Happening Right Now
- : IMDX reported Q2 2026 results with a net loss of $11.3 million, alongside timely progress on FDA review of its GraftAssureDx kidney-transplant test.
- : iMDx filed to register 1.75 million more shares under its equity incentive plan, worth up to about $8.26 million.
- : A Lancet Regional Health study highlighted iMDx's GraftAssure assay for guiding kidney transplant drug treatment, alongside confirmed Medicare reimbursement for treatment-response monitoring.
- : A new Medicare policy expands coverage and allowed testing frequency for iMDx's dd-cfDNA GraftAssure assay portfolio, supporting commercial adoption.
- : A published study showed iMDx's GraftAssure CM-score outperforming standard tests for detecting kidney transplant rejection, supporting its pending FDA marketing application.
Raise routes on file: effective shelf + effective S-1 · latest dilution event 264 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Feb 12, 2026 · Offering
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Effective
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Series A Redeemable Convertible Preferred Stock
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
ATM program
Issued 2024
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
ATM program
Issued 2021
Total capacity
Sold to date
Remaining capacity
- Sales agent
- Agreement date
- Commission
S-3 shelf registration
Issued 2024
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2024
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2024
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
Registered direct offering
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your IMDX trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
